Mitochondrial OXPHOS restricts SARS-CoV-2 replication.
Level 5 - mechanism / opinion, no new human data
In vitro mechanistic laboratory study without human clinical subjects
PubMed 42234733 · doi:10.1126/sciadv.adz3081
What was done
Researchers investigated the role of mitochondrial oxidative phosphorylation (OXPHOS) in SARS-CoV-2 infection using human ACE2-expressing A549 lung cells. OXPHOS was disrupted through mitochondrial DNA (mtDNA) depletion (rho 0 cells), chemical inhibition of OXPHOS complexes, or inhibition of mitochondrial translation with chloramphenicol. They evaluated viral production, replication center dynamics, kinetics of viral particle release, requirement for glycolysis, innate immune pathway activation, and the effect of restoring OXPHOS via mtDNA reintroduction.
What was found
OXPHOS inhibition increased SARS-CoV-2 viral production by approximately 5- to 100-fold in A549-ACE2 cells. Viral replication centers were larger and infectious particle release occurred approximately 2 hours earlier compared to wild-type cells. Enhanced replication required increased glycolytic capacity but was independent of innate immune pathway activation differences. Reintroducing maternal lineage mtDNA restored OXPHOS and reversed both elevated viral replication and associated glycolytic changes.
Why it matters
This study demonstrates that mitochondrial OXPHOS functions as an intrinsic metabolic restriction factor against SARS-CoV-2 replication, showing that metabolic shifts toward glycolysis directly accelerate viral life cycles.
Limits
The study is restricted to in vitro experiments in a single engineered human lung cell line (A549-ACE2). No in vivo animal models, clinical human tissue data, exact sample sizes (n), or statistical variance metrics were reported in the abstract.
Cited by
- supports SARS-CoV-2 replicates more efficiently in a glycolytic environment.